Results of ALLHAT: Is this the final answer regarding initial antihypertensive drug therapy?

Archives of Internal Medicine

Volumn 163, Issue 11, 2003, Pages 1269-1273

  Moser, Marvin ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; AMLODIPINE; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHLORTALIDONE; CLONIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXAZOSIN; HYDRALAZINE; LISINOPRIL; RESERPINE;

ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; DEMOGRAPHY; DIABETES MELLITUS; DIABETIC KETOACIDOSIS; DRUG COST; DRUG INDICATION; DRUG MEGADOSE; ELECTROLYTE DISTURBANCE; HEALTH CARE COST; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART VENTRICLE ARRHYTHMIA; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; KIDNEY FAILURE; METABOLIC DISORDER; NOTE; PRIORITY JOURNAL; PUBLICATION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK BENEFIT ANALYSIS; TREATMENT OUTCOME; UNITED STATES;

AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; CORONARY DISEASE; DIURETICS; DRUG THERAPY, COMBINATION; HUMANS; HYPERTENSION; RANDOMIZED CONTROLLED TRIALS;

EID: 0038687520     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.163.11.1269     Document Type: Note

References (51)

1. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002; 288:2981-2997.
2. Cushman WC, Ford CE, Cutler JA, et al. Success and predictors of blood pressure control in diverse North American settings: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Clin Hypertens (Greenwich). 2002;4:393-404.
3. Antihypertensive Therapy and Lipid Lowering Heart Attack Trial (ALLHAT) Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. JAMA. 2000;283:1967-1975.
4. Wing LMH, Reid CM, Ryan P, et al, for the Second Australian National Blood Pressure Study Group. A comparison of outcomes with angiotensin-converting enzyme inhibitors and diuretics in the treatment of hypertension in the elderly. N Engl J Med. 2003;348:583-592.
5. Ames RP. The influence of non β-blocking drugs on the lipid profile: are diuretics outclassed as initial therapy for hypertension? Am Heart J. 1987; 114:998-1006.
6. Zussman RM. Alternatives to traditional antihypertensive therapy [editorial]. Hypertension. 1986; 8:837-842.
7. Houston MC. New insights and new approaches for the treatment of essential hypertension: selection of therapy based on coronary heart disease risk factor analysis, hemodynamic profiles, quality of life, and subsets of hypertension. Am Heart J. 1989;117:911-949.
8. Hebert P, Moser M, Mayer J, Hennekens CH. Recent evidence of drug therapy on mild to moderate hypertension and decreased risk of coronary heart disease. Arch Intern Med. 1993;153:578-581.
9. McInnes GT, Yeo WW, Ramsey LE, et al. Cardiotoxicity and diuretics: much speculation, little substance. J Hypertens. 1992;10:317-335.
10. Moser M. Suppositions and speculations: their possible effects on treatment decisions in the management of hypertension. Am HeartJ. 1989;118: 1362-1369.
11. Freis ED. Critique of the clinical importance of diuretic induced hypokalemia and elevated cholesterol levels. Arch Intern Med. 1989;149:2649-2658.
12. Moser M. Current hypertension management: separating fact from fiction. Cleve Clin J Med 1993; 60:27-37.
13. Thompson WG. An assault on old friends: Thiazide diuretics under siege. Am J Med Sci. 1990; 300:152-158.
14. Moser M. Clinical trials and their effect on medical therapy: the Multiple Risk Factor Intervention Trial. Am Heart J. 1984;107:616-618.
15. Moser M. Clinical trials, diuretics and the management of mild hypertension. Arch Intern Med. 1984;144:789-792.
16. Moser M. Diuretics in the management of hypertension. Med Clin North Am. 1987;71:935-946.
17. Moser M, Menard J. Clinical significance of the metabolic effects of antihypertensive drugs. J Hum Hypertens. 1993;7(suppl 1):S50-S55.
18. Papademetriou V, Fletcher R, Khatri IM, Freis ED. Thiazide therapy is not a cause of arrhythmia in patients with systemic hypertension. Arch Intern Med. 1988;148:1272-1276.
19. Holland OB, Nixon JV, Kuhnert I. Diuretic-induced ventricular ectopic activity. Am J Med, 1981;70:762-768.
20. Hollifield JW. Potassium and magnesium abnormalities: diuretics and arrhythmias in hypertension. Am J Med. 1984;77:28-32.
21. Moser M, Hebert PR. Prevention of disease progression, left ventricular hypertrophy and congestive heart failure in the hypertension treatment trials. J Am Coll Cardiol. 1996;27:1214-1218.
22. The Multiple Risk Factor Intervention Trial Research Group. Mortality rates after 10.5 years for participants in the Multiple Risk Factor Intervention Trial. JAMA. 1990;263:1795-1801.
23. SHEP Cooperative Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA. 1991;265:3255-3264.
24. The Fifth Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med. 1993;153:154-183.
25. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med. 1997;157:2413-2446.
26. Manolio TA, Cutler JA, Furberg CD, et al. Trends in pharmacologic management of hypertension in the United States. Arch Intern Med. 1995;155: 829-837.
27. Moser M, Blaufox MD, Freis, et al. Who really determines your patients' prescriptions? JAMA. 1991;265:498-500.
28. Moser M. Why are physicians not prescribing diuretics more frequently in the management of hypertension? JAMA. 1998;279:1813-1816.
29. Moser M. Cost containment in the management of hypertension. Ann Intern Med. 1987;107:107-109.
30. Moser M. The cost of treating hypertension: can we keep it under control without compromising the level of care? Am J Hypertens. 1998;11:120S-127S.
31. New trials in older hypertensives [editorial]. Lancet. 1991;338:1299-1300.
32. Moser M, Gifford R. Diuretic therapy and the risk of cardiac arrest. N Engl J Med. 1994;331:1235-1236.
33. Moser M. The diuretic dilemma and the management of mild hypertension. Drugs. 1986;31 (suppl 4):56-67.
34. Moser M. In defense of traditional antihypertensive therapy. Hypertension. 1988;12:324-326.
35. Moser M. Diuretics should continue to be recommended as initial therapy in the treatment of hypertension? In: Puschett JB, Greenberg A. Diuretics IV, Chemistry, Pharmacology and Clinical Applications. New York, NY: Exerpta Medica; 1993.
36. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Lancet. 2000;355: 1955-1964.
37. Neaton JD, Grimm RH, Prineas RJ, et al, for the Treatment of Mild Hypertension Study Research Group. Treatment of mild hypertension study: final results. JAMA. 1993;270:713-724.
38. Moser M, Setaro J. Antihypertensive drug therapy and regression of left ventricular hypertrophy: review with a focus on diuretics. Eur Heart J. 1991; 12:1034-1039.
39. Moser M, Ross H. The treatment of hypertension in diabetic patients. Diabetes Care, 1993;16:542-547.
40. Hansson L, Lindholm LH, Ekbom T, et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity in the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999; 354:1751-1756.
41. Moser M. Can the cost of care be contained and quality of care maintained in the management of hypertension? Arch Intern Med. 1994;154:1665-1672.
42. Moser M. Relative efficacy of, and some adverse reactions to, different antihypertensive regimens. Am J Cardiol. 1989;63:2B-7B.
43. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Nephropathy (RENAAL). N Engl J Med. 2001;345: 861-869.
44. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint Reduction in Hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995-1003.
45. Heart Outcome Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and the MICRO HOPE substudy. Lancet. 2000; 355:253-259.
46. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes IDNT). N Engl J Med. 2001; 345:851-860.
47. Agodoa L, Appel L, Bakris G, et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis, African American Study of Kidney Disease (AASK): a randomized controlled trial. JAMA. 2001;285:2719-2728.
48. Parving HH Lennert H, Brochner-Mortensen J. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes: Irbesartan Microalbuminuria Type II Diabetes in Hypertensive Patients (IRMA II). N Engl J Med. 2001;345:870-878.
49. Moser M. Diuretics revisited - again. J Clin Hypertens (Greenwich). 2001;3:136-138.
50. Moser M. Treating hypertension: calcium channel blockers, diuretics, β-blockers, ACE inhibitors: is there a difference? J Clin Hypertens (Greenwich). 2000;2:301-304.
51. Moser M. Myths, Misconceptions and Heroics-The Story of the Treatment of Hypertension From the 1930s. Darien, Conn: LeJacq Communications; 2002.